Current treatment options of T cell-associated immunotherapy in multiple myeloma.

about

Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.

P2860

Q38685785-1F8C5F71-0B5B-4122-B88C-E08FFFBF10AE

P2860

Current treatment options of T cell-associated immunotherapy in multiple myeloma.

Item

http://www.wikidata.org/entity/Q39102170

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Current treatment options of T cell-associated immunotherapy in multiple myeloma.

@en

Current treatment options of T cell-associated immunotherapy in multiple myeloma.

@nl

type

Item

label

Current treatment options of T cell-associated immunotherapy in multiple myeloma.

@en

Current treatment options of T cell-associated immunotherapy in multiple myeloma.

@nl

prefLabel

Current treatment options of T cell-associated immunotherapy in multiple myeloma.

@en

Current treatment options of T cell-associated immunotherapy in multiple myeloma.

@nl

P1476

Current treatment options of T cell-associated immunotherapy in multiple myeloma.

@en

P2093

Hailing Liu

http://www.w3.org/2001/XMLSchema#string

Shan Meng

http://www.w3.org/2001/XMLSchema#string

Wanggang Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Application of serum SELDI proteomic patterns in diagnosis of lung cancer

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab

T-cell receptor gene therapy--ready to go viral?

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma

Mixed T cell receptor dimers harbor potentially harmful neoreactivity.

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention

Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.

Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations.

P2888

s10238-017-0450-9

P304

431-439

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10238-017-0450-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yunbao Pan

Fuling Zhou

P577

2017-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28120217

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

Current treatment options of T cell-associated immunotherapy in multiple myeloma.

about

P2860

P2860

Current treatment options of T cell-associated immunotherapy in multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921